Motley Fool
2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $1,000
📈
AI Sentiment
Highly Positive
8/10
- Home
- LLY
as of 03-06-2026 3:38pm EST
$985.50
+$2.24
+0.23%
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
| Founded: | 1876 | Country: | United States |
| Employees: | N/A | City: | INDIANAPOLIS |
| Market Cap: | 950.7B | IPO Year: | 2007 |
| Target Price: | $1174.53 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 19 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 22.95 | EPS Growth: | 95.99 |
| 52 Week Low/High: | $623.78 - $1133.95 | Next Earning Date: | 05-04-2026 |
| Revenue: | $65,179,000,000 | Revenue Growth: | 44.70% |
| Revenue Growth (this year): | 27.04% | Revenue Growth (next year): | 16.26% |
| P/E Ratio: | 42.77 | Index: | |
| Free Cash Flow: | N/A | FCF Growth: | +138.62% |
AI-Powered LLY Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 77.16%
77.16%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Eli Lilly and Company (LLY)
LILLY ENDOWMENT INC
Sell
10% Owner
LLY Jan 7, 2026
Avg Cost/Share
$1,101.51
Shares
292,148
Total Value
$322,380,730.46
Owned After
91,896,978
LILLY ENDOWMENT INC
Sell
10% Owner
LLY Jan 5, 2026
Avg Cost/Share
$1,085.01
Shares
1,390
Total Value
$1,508,165.29
Owned After
91,896,978
SEC Form 4
LILLY ENDOWMENT INC
Sell
10% Owner
LLY Dec 29, 2025
Avg Cost/Share
$1,085.04
Shares
3,593
Total Value
$3,898,530.76
Owned After
91,896,978
SEC Form 4
LILLY ENDOWMENT INC
Sell
10% Owner
LLY Dec 24, 2025
Avg Cost/Share
$1,085.17
Shares
2,629
Total Value
$2,852,919.82
Owned After
91,896,978
SEC Form 4
LILLY ENDOWMENT INC
Sell
10% Owner
LLY Dec 23, 2025
Avg Cost/Share
$1,085.04
Shares
240
Total Value
$260,409.12
Owned After
91,896,978
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jan 7, 2026 | Sell | $1,101.51 | 292,148 | $322,380,730.46 | 91,896,978 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jan 5, 2026 | Sell | $1,085.01 | 1,390 | $1,508,165.29 | 91,896,978 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Dec 29, 2025 | Sell | $1,085.04 | 3,593 | $3,898,530.76 | 91,896,978 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Dec 24, 2025 | Sell | $1,085.17 | 2,629 | $2,852,919.82 | 91,896,978 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Dec 23, 2025 | Sell | $1,085.04 | 240 | $260,409.12 | 91,896,978 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 4, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 4, 2026 · 100% conf.
AI Prediction BUY
1D
+1.14%
$1117.00
5D
+4.74%
$1156.70
20D
+7.86%
$1191.16
Price: $1104.36 Prob +5D: 100% AUC: 1.000
0000059478-26-000008
lly-202602040000059478false00000594782026-02-042026-02-040000059478us-gaap:CommonClassAMember2026-02-042026-02-040000059478lly:A1.625NotesDueJune22026Member2026-02-042026-02-040000059478lly:A2.125NotesDueJune32030Member2026-02-042026-02-040000059478lly:A625Notesdue2031Member2026-02-042026-02-040000059478lly:A500NotesDue2033Member2026-02-042026-02-040000059478lly:A6.77NotesDueJanuary12036Member2026-02-042026-02-040000059478lly:A1625NotesDue2043Member2026-02-042026-02-040000059478lly:A1.700Notesdue2049Member2026-02-042026-02-040000059478lly:A1125NotesDue2051Member2026-02-042026-02-040000059478lly:A1375NotesDue2061Member2026-02-042026-02-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 4, 2026
ELI LILLY AND COMPANY
(Exact Name of Registrant as Specified in its Charter)
Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
Lilly Corporate Center Indianapolis,Indiana46285 (Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (317) 276-2000
Not Applicable (Former Name or Former Address, if Changed Since Last Report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock (no par value)LLYNew York Stock Exchange 1.625% Notes due 2026LLY26New York Stock Exchange 2.125% Notes due 2030LLY30New York Stock Exchange 0.625% Notes due 2031LLY31New York Stock Exchange 0.500% Notes due 2033LLY33New York Stock Exchange 6.77% Notes due 2036LLY36New York Stock Exchange 1.625% Notes due 2043LLY43New York Stock Exchange 1.700% Notes due 2049LLY49ANew York Stock Exchange 1.125% Notes due 2051LLY51New York Stock Exchange 1.375% Notes due 2061LLY61New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.
Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated February 4, 2026, announcing the financial results of Eli Lilly and Company for the quarter and year ended December 31, 2025.
Item 9.01. Financial Statements and Exhibits.
Exhibit No.Description 99.1 Press Release of Eli Lilly and Company, dated February 4, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ELI LILLY AND COMPANY
(Registrant)
By:/s/ Donald A. Zakrowski Name:Donald A. Zakrowski Title:Senior Vice President, Finance, and Chief Accounting Officer Date: February 4, 2026
2025 Q3 Q3 2025 Earnings
8-K Oct 30, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 30, 2025
0000059478-25-000251
lly-202510300000059478false00000594782025-10-302025-10-300000059478us-gaap:CommonClassAMember2025-10-302025-10-300000059478lly:A1.625NotesDueJune22026Member2025-10-302025-10-300000059478lly:A2.125NotesDueJune32030Member2025-10-302025-10-300000059478lly:A625Notesdue2031Member2025-10-302025-10-300000059478lly:A500NotesDue2033Member2025-10-302025-10-300000059478lly:A6.77NotesDueJanuary12036Member2025-10-302025-10-300000059478lly:A1625NotesDue2043Member2025-10-302025-10-300000059478lly:A1.700Notesdue2049Member2025-10-302025-10-300000059478lly:A1125NotesDue2051Member2025-10-302025-10-300000059478lly:A1375NotesDue2061Member2025-10-302025-10-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 30, 2025
ELI LILLY AND COMPANY
(Exact Name of Registrant as Specified in its Charter)
Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
Lilly Corporate Center Indianapolis,Indiana46285 (Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (317) 276-2000
Not Applicable (Former Name or Former Address, if Changed Since Last Report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock (no par value)LLYNew York Stock Exchange 1.625% Notes due 2026LLY26New York Stock Exchange 2.125% Notes due 2030LLY30New York Stock Exchange 0.625% Notes due 2031LLY31New York Stock Exchange 0.500% Notes due 2033LLY33New York Stock Exchange 6.77% Notes due 2036LLY36New York Stock Exchange 1.625% Notes due 2043LLY43New York Stock Exchange 1.700% Notes due 2049LLY49ANew York Stock Exchange 1.125% Notes due 2051LLY51New York Stock Exchange 1.375% Notes due 2061LLY61New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.
Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated October 30, 2025, announcing the financial results of Eli Lilly and Company for the quarter ended September 30, 2025.
Item 9.01. Financial Statements and Exhibits.
Exhibit No.Description 99.1 Press Release of Eli Lilly and Company, dated October 30, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ELI LILLY AND COMPANY
(Registrant)
By:/s/ Donald A. Zakrowski Name:Donald A. Zakrowski Title:Senior Vice President, Finance, and Chief Accounting Officer Date: October 30, 2025
2025 Q2 Q2 2025 Earnings
8-K Aug 7, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 7, 2025
0000059478-25-000202
lly-202508070000059478false00000594782025-08-072025-08-070000059478us-gaap:CommonClassAMember2025-08-072025-08-070000059478lly:A1.625NotesDueJune22026Member2025-08-072025-08-070000059478lly:A2.125NotesDueJune32030Member2025-08-072025-08-070000059478lly:A625Notesdue2031Member2025-08-072025-08-070000059478lly:A500NotesDue2033Member2025-08-072025-08-070000059478lly:A6.77NotesDueJanuary12036Member2025-08-072025-08-070000059478lly:A1625NotesDue2043Member2025-08-072025-08-070000059478lly:A1.700Notesdue2049Member2025-08-072025-08-070000059478lly:A1125NotesDue2051Member2025-08-072025-08-070000059478lly:A1375NotesDue2061Member2025-08-072025-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 7, 2025
ELI LILLY AND COMPANY
(Exact Name of Registrant as Specified in its Charter)
Indiana 001-06351 35-0470950 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
Lilly Corporate Center Indianapolis,Indiana46285 (Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (317) 276-2000
Not Applicable (Former Name or Former Address, if Changed Since Last Report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock (no par value)LLYNew York Stock Exchange 1.625% Notes due 2026LLY26New York Stock Exchange 2.125% Notes due 2030LLY30New York Stock Exchange 0.625% Notes due 2031LLY31New York Stock Exchange 0.500% Notes due 2033LLY33New York Stock Exchange 6.77% Notes due 2036LLY36New York Stock Exchange 1.625% Notes due 2043LLY43New York Stock Exchange 1.700% Notes due 2049LLY49ANew York Stock Exchange 1.125% Notes due 2051LLY51New York Stock Exchange 1.375% Notes due 2061LLY61New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.
Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated August 7, 2025, announcing the financial results of Eli Lilly and Company for the quarter ended June 30, 2025.
Item 9.01. Financial Statements and Exhibits.
Exhibit No.Description 99.1 Press Release of Eli Lilly and Company, dated August 7, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ELI LILLY AND COMPANY
(Registrant)
By:/s/ Donald A. Zakrowski Name:Donald A. Zakrowski Title:Senior Vice President, Finance, and Chief Accounting Officer Date: August 7, 2025
Latest Eli Lilly and Company News
LLY Breaking Stock News: Dive into LLY Ticker-Specific Updates for Smart Investing
Investor's Business Daily
Hims And Hers Surges 40% On Deal To Sell Novo Nordisk Obesity Drugs
📈
AI Sentiment
Highly Positive
8/10
Motley Fool
Where Will Eli Lilly Stock Be in 10 Years?
24/7 Wall St.
Hims & Hers Surprise Rescue: Stock Explodes 40% on GLP-1 Truce
📈
AI Sentiment
Highly Positive
9/10
Simply Wall St.
Eli Lilly Weighs Employer Growth Potential Against Fresh Actos Legal Risk
📊
AI Sentiment
Positive
6/10
Compare LLY vs Leading Stocks
See how LLY stacks up against similar companies in the market
Head-to-Head Comparisons
More Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "LLY Eli Lilly and Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.